Trial intelligence / Profile preview

ADDORA adalimumab therapeutic drug monitoring dose optimization trial in rheumatoid arthritis

NL-OMON26185Recruiting

Sponsor
Reade Rheumatology Research Institute
Start
Dec 2019
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reade Rheumatology Research Institute. Started Dec 2019; status: recruiting.

02

Drugs

03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on NL-OMON26185.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON26185.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call